Premenstrual syndrome. Pathogenetic aspects of treatment

Authors

  • Т. Ф. Татарчук SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, Ukraine https://orcid.org/0000-0002-5498-4143
  • Н. Ф. Захаренко SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, Ukraine
  • I. П. Маноляк SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2018.43.50-54

Keywords:

premenstrual syndrome, micronized progesterone, dysmenorrhea, Proginorm

Abstract

The purpose of the described research was to study the effectiveness of the use of micronized progesterone in the treatment of premenstrual syndrome. 68 women of reproductive age from 18 to 40 years old (mean age 31.2 ± 5.3 years) with premenstrual syndrome of mild and moderate severity were studied. The women were randomized into two groups: the treatment group (n = 35) and the control group (n = 33). The study groups were comparable in age and forms of premenstrual syndrome.

Patients of treatment group received therapy with Proginorm OVO, 200 mg per day from 16 to 25 days of the menstrual cycle for three cycles. The drug Proginorm OVO was chosen taking into account its properties, which are similar to the properties of natural endogenous progesterone in the presence of progestogenic, antiestrogenic and light antiandrogenic and aldosterone effects. The women of control group did not receive drugs. To alleviate the condition, for patients of both groups were recommended non-drug measures: optimization of work and rest, balanced nutrition, active lifestyle with moderate physical exertion.

Authors concluded that the use of micronized progesterone is appropriate and effective in treating the main manifestations of premenstrual syndrome, especially with regard to pain, changes in behavior and symptoms of fluid retention in the body. In this case, the period of premenstrual syndrome manifestations treatment is advisable to continue up to 6 months, preventing the rapid recovery of symptoms after cessation of therapy.

Author Biographies

Т. Ф. Татарчук, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department

Н. Ф. Захаренко, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

MD, senior researcher at the Endocrine Gynecology Department

I. П. Маноляк, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”

Junior researcher at the Endocrine Gynecology Department

References

  1. Tatarchuk, T.F., Zakharenko, N.F., Manolyak, I.P., Kovbasii, V.P. “Improvement of the treatment tactics of women with endometriosis.” Reproductive endocrinology 4.18 (2014): 24–7.
  2. Dennerstein, L., Lehert, P., Keung, L.S., et al. “Asian study of effects of premenstrual symptoms on activities of daily life.” Menopause Int 16.4 (2010): 146–51.
  3. Bridou, M., Aguerre, C. “Premenstrual symptomatology, somatization and physical anhedonia.” Encephale 39.6 (2013): 432–8.
  4. Kuznetsova, I.V., Konovalov, V.A. “Modern therapy of premenstrual syndrome (literature review).” Gynecology 15.3 (2013): 20–25.
  5. Torchinov, A.M., Bardenstein, L.M., Polukhova, E.V., Firichenko, V.I. “Premenstrual syndrome (issues of pathogenesis, clinical presentation and treatment).” Gynecology 2 (2010): 21–5.
  6. Ziomkiewicz, A., Pawlowski, B., Ellison, P.T., et al. “Higher luteal progesterone is associated with low levels of premenstrual aggressive behavior and fatigue.” Biol Psychol 91.3 (2012): 376–82.
  7. Mezhevitinova, E.A. “Magnesium deficiency states in gynecological practice: clinical evaluation and methods of correction.” Questions of gynecology, obstetrics and perinatology 4 (2007): 91–8.
  8. Yakovleva, E.B., Babenko, O.M., Pilipenko, O.N. “Premenstrual syndrome. To help the practitioner.” Reproductive Endocrinology 4.18 (2014): 30–4.
  9. Pozdnyak, A.O. “Drug therapy of premenstrual syndrome.” Obstetrics and Gynecology 8 (2011): 117–20.
  10. Perez-Lopez, F.R., Chedraui, P., Perez-Roncero, G., et al. “Premenstrual Syndrome and Premenstrual Dysphoric Disorder: Symptoms and Cluster Influences.” The Open Psychiatry Journal 3 (2009): 47–57.
  11. Ford, O., Lethaby, A., Roberts, H., Mol, B.W. “Progesterone for premenstrual syndrome.” Cochrane Database Syst Rev 3 (2012): CD003415.

Downloads

Published

2018-12-03

How to Cite

Татарчук, Т. Ф., Захаренко, Н. Ф., & Маноляк I. П. (2018). Premenstrual syndrome. Pathogenetic aspects of treatment. REPRODUCTIVE ENDOCRINOLOGY, (43), 50–54. https://doi.org/10.18370/2309-4117.2018.43.50-54

Issue

No. 43 (2018)

Section

Gynecology

License

Copyright (c) 2018 Т. Ф. Татарчук, Н. Ф. Захаренко, I. П. Маноляк

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.